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Abstract
Long-term health-related quality of life is compared between patients with rectal cancer preoperatively treated
with long-course chemo radiotherapy (CRT) or with short-course radiotherapy. Apart from less satisfaction
with urinary function reported by patients who had CRT, no clinically relevant differences in health-related
quality of life and patient-reported symptoms between patients who had CRT and short-course radiotherapy
were found at 5 years after rectal cancer treatment.
Background: Both preoperative short-course radiotherapy (SC-PRT) and preoperative long-course chemo radio-
therapy (CRT) have shown to reduce local recurrence rates after total mesorectal excision (TME), but neither
resulted in improved survival. This study compared the long-term health-related quality of life (HRQL) and symp-
toms between CRT and SC-PRT. Methods: Patients who were preoperatively treated with a total dose of 50.0 to
50.4 Gy for locally advanced rectal cancers were identiﬁed from 2 hospital registries. Starting from 2011, all patients
who were disease-free in the study population (n ¼ 105) were sent a HRQL-questionnaire composed of the Eu-
ropean Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and questions on bowel and urinary
function. Patients who underwent SC-PRT in the TME trial were used as a reference group. Results: HRQL results
from 85 patients receiving CRT (81.0%), with a median follow-up time of 58 months, were compared with the results
of patients who underwent SC-PRT (n ¼ 306). Apart from more nausea and vomiting reported by patients receiving
CRT (mean score for CRT 5.9 vs. 1.3 for SC-PRT; P < .01; not clinically relevant) and less satisfaction with urinary
function indicated by patients who received CRT (mean score for CRT 71.2 vs. 81.2 for SC-PRT; P < .01), no
signiﬁcant differences were found in HRQL and symptoms between patients who received CRT and SC-PRT.
Conclusions: This analysis of HRQL in patients who received CRT shows no clinically relevant differences in long-
term HRQL and symptoms between patients who received CRT and SC-PRT, apart from less satisfaction with
urinary function reported by patients who received CRT. These results indicate that both approaches have a
comparable impact on long-term HRQL.
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HRQL After (Chemo) Radiotherapy for Rectal CancerIntroduction on the TME trial design are reported in previous studies.
8-11 TheThe surgical treatment for resectable rectal cancer consists of a
total mesorectal excision (TME). Depending on the tumor location,
inﬁltration depth of the tumor, and lymph node involvement,
treatment is combined with preoperative short-course radiotherapy
(SC-PRT) or preoperative long-course chemo radiotherapy (CRT).
There is no international consensus on the use of these treatment
schedules or the most appropriate patient selection for these
schedules. Both SC-PRT and CRT have shown to reduce local
recurrence rates.1-6 However, none of these neoadjuvant therapies
resulted in an improved overall survival,2-6 which emphasizes the
importance of knowledge of health-related quality of life (HRQL)
after these different treatment schedules. A randomized Polish trial
compared the HRQL after SC-PRT (5  5 Gy) and CRT (28 
1.8 Gy, 5-ﬂuorouracil and leucovorin) followed by TME. After a
median follow-up time of 12 months, no difference in HRQL was
found between these groups.7 However, since SC-PRT uses a higher
dose per fraction in a short overall treatment time, there may be a
risk for more late radiation-related toxicity compared with CRT.
Long-term reported HRQL outcomes can provide additional in-
formation, which can be used to inform patients and healthcare
providers and support evidence-based shared decision-making.
Therefore, the aim of this study is to compare patient-reported
symptoms and HRQL of patients treated with CRT to patients
treated with SC-PRT for rectal cancer with a long follow-up time.
Patients and Methods
Study Population and Treatment
For this retrospective study, patients with locally advanced rectal
cancer treated with long-course (chemo) radiotherapy between
January 2003 and October 2010 were identiﬁed in the registries of
the Leiden University Medical Center (LUMC) and Radiotherapy
Center West (RCW). Locally advanced rectal cancer was deﬁned as
a tumor with growth into an adjacent organ, in close proximity to
the mesorectal fascia, or any tumor accompanied by N2-status.
Exclusion criteria were prior malignancies, local recurrences, meta-
static disease at presentation, a higher received dose than 50.4 Gy,
and prior pelvic radiotherapy.
Patients were treated with chemotherapy (capecitabine alone,
capecitabine and oxaliplatin, 5-ﬂuorouracil and leucovorin, or
capacetibine and bevacizumab) and a total radiation dose of 50 to
50.4 Gy in daily fractions of 1.8 to 2.0 Gy delivered by a 4-ﬁeld
technique. The primary tumor and the mesentery containing the
perirectal and presacral nodes, as well as the internal iliac nodes up
to the S1/S2 junction, were included in the clinical target volume, as
well as the perineum if an abdominoperineal resection (APR) was
planned. Otherwise, the lower border was at least 3 cm caudally to
the primary tumor. Five to 8 weeks after the last radiation treat-
ment, patients underwent surgery according to the TME principles.
Patients treated with SC-PRT in the Dutch TME trial were used
as a reference group. These patients had a clinically resectable
adenocarcinoma without evidence of distant metastases and an
inferior margin of the tumor located below the level of S1/S2 and
within 15 cm of the anal verge. Patients who received SC-PRT were
treated with 25 Gy in 5 fractions delivered with a 3 or 4-ﬁeld
technique. Within 10 days of the start of radiotherapy, patients
underwent surgery according to the TME principles. More detailsClinical Colorectal Cancer September 2016local ethics committee approved this retrospective study, and
informed consent for the questionnaire was obtained from all
patients.
Measurements
Starting from June 2011, HRQL questionnaires were sent to
patients who were disease-free. Patients who did not respond
received 2 reminders. Patients were asked to complete the European
Organization for Research and Treatment of Cancer (EORTC) core
questionnaire (EORTC QLQ-C30) and an additional questionnaire
on bowel and urinary function. The EORTC QLQ-C30 is a general
cancer HRQL-questionnaire composed of 30 items. It includes a
global health status scale, 5 functional scales (physical, role,
emotional, cognitive, social), 3 symptom scales (fatigue, pain,
nausea and vomiting), and 6 single-item scales (dyspnea, insomnia,
appetite loss, constipation, diarrhea, and ﬁnancial difﬁculties).12
The additional questionnaire on bowel and urinary function was
previously used in the Dutch TME trial.9 All items of this ques-
tionnaire are reported in the Appendix. Scores of the additional
questionnaire on urinary and bowel function were compared be-
tween the study group and the patients of the TME trial who
received SC-PRT (n ¼ 306) after a median follow-up of 5 years.9
However, since the QLQ-C30 was not included in the HRQL
questionnaire sent to patients in the TME trial at 5 years, but was
included in the questionnaire sent at 14 years, the 14-year QLQ-
C30 scores of the SC-PRT were used. This is based on a previous
longitudinal study of the TME trial, which reported that the QLQ-
C30 scores between 5 and 14 years after treatment were mostly only
inﬂuenced by age.13 This is also supported by population-based
studies.14-17 Likert-type scales were used for all questions, except
for 3 dichotomous questions. All single-item and subscale responses
were linearly converted to 0 to 100 scales. A higher score for
functioning reﬂects better functioning, whereas a higher score for
symptoms represents a higher level of symptoms and decreased
HRQL.
Statistics
Analyses were performed with IBM SPSS Statistics, version 20.0.
The Reverse Kaplan-Meier methodology was used to compute the
median follow-up time. Mean scores were calculated, and missing
values were handled according to the guidelines provided by the
EORTC Quality of Life Group.18 To prevent against false-positive
results owing to multiple testing, a 2-sided P value of .01 was
regarded statistically signiﬁcant. Differences in mean scores were
considered clinically relevant if the differences were larger than 5
points on a scale of 100 points.19
Matching of the reference data was based on previous analysis in
the Dutch TME trial (data not shown). This analysis showed that
the T status, N status, the positive or negative circumferential
resection margin, tumor height, type of operation, and presence of a
stoma did not inﬂuence HRQL and urinary symptoms. However,
HRQL was associated with gender and age. Therefore, the reference
data of the TME trial were matched for age and gender with the
CRT group. Linear regression and logistic regression models were
used to compare the HRQL and symptoms between the groups that
received CRT and SC-PRT.
Table 1 Patient and Clinical Characteristics for the HRQL Responders
Characteristics
CRT (n [ 85) SC-PRT (n [ 306)
No. of Patients % No. of Patients %
Age, years
Median 69 68
Range 26-89 40-91
Gender
Male 55 64.7 199 65.0
Female 30 35.3 107 35.0
TNM stage
0 0 0 8 2.6
I 1 1.2 140 45.8
II 14 16.5 84 27.5
III 64 75.3 74 24.2
IV 0 0 0 0
Unknown 6 7.1 0 0
Distance to anal verge, cm
0-5 32 37.6 86 28.1
5-10 30 35.3 123 40.2
10-20 16 18.8 96 31.4
Unknown 7 8.2 1 0.3
Operation type
LAR 20 23.5 200 65.4
APR 47 55.3 91 29.7
Hartmann 17 20.0 15 4.9
No resection 1 1.2 0 0
Stoma present
Yes 67 78.8 129 42.2
No 18 21.2 177 57.8
To compare HRQL, data of the SC-PRT patients were matched for age and gender with the CRT patients.
Abbreviations: APR ¼ Abdominoperineal resection; CRT ¼ preoperative long-course chemo radiotherapy; HRQL ¼ health-related quality of life; LAR ¼ low anterior resection; SC-PRT ¼ preoperative
short-course radiotherapy.
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Study Population and Compliance
In total, 247 patients with locally advanced rectal cancer were
treated between January 2003 and October 2010. Of these, 189
patients (123 LUMC; 66 RCW) met the inclusion criteria. In June
2011, 105 of the 189 study patients were disease-free. These pa-
tients were sent a HRQL questionnaire, and 85 patients responded
(response rate, 81.0%). Except for 13 patients (15.3%), all re-
sponders received chemotherapy during long-course radiotherapy.
For most patients (70.6%), concurrent chemotherapy consisted of
twice-daily oral capecitabine (825 mg/m2), 6 patients (7.1%)
received capecitabine and oxaliplatin, 1 patient (1.2%) received
5-ﬂuorouracil and leucovorin, and 5 patients (5.9%) received
capecetibine and bevacizumab. The median follow-up time since
diagnosis was 58 months (range, 15-98 months).
Questions of the QLQ-C30 were completed for all items in
92.9% of the responders. With regard to the questions on bowel
function, patients without a stoma completed all items in 72.2%
and patients with stoma in 77.6%. When up to 2 missing items
were allowed, these rates were 88.9% and 92.6%, respectively.Patient characteristics of the patients who received CRT and SC-
PRT are listed in Table 1. As expected, patients who received
CRT had more advanced TNM stages compared with patients who
received SC-PRT, and 75.3% of the patients who received CRT
underwent an APR or Hartmann operation compared with 34.6%
of those who received SC-PRT. As described in the methods sec-
tion, these differences in patient characteristics did not inﬂuence
HRQL or urinary symptoms.
Bowel and Urinary Symptoms
No signiﬁcant differences in bowel or urinary function were
found between patients who received CRT and SC-PRT, matched
for age and gender (Table 2). However, for bowel symptoms, trends
were observed towards increased anal mucus loss and more limita-
tion in work or household activities caused by bowel function in the
patients who received CRT. For urinary symptoms, patients who
received CRT showed a trend towards more urine-retention after
miction and a trend towards more difﬁculty to start miction.
Furthermore, patients who received CRT were signiﬁcantly less
satisﬁed with their urinary function.Clinical Colorectal Cancer September 2016 - e95
Table 2 Bowel and Urinary Function
Mean Scores
CRT
Mean Scores
SC-PRT P
Bowel function
Fecal
incontinence
42.2 34.6 .34
Fecal
incontinence at
night
22.9 13.4 .15
Ability to delay
bowel emptying
65.6 66.5 .86
Anal blood loss 6.3 4.8 .78
Anal mucus
loss
22.9 11.2 .07
Peristomal skin
irritation
18.2 16.8 .54
Stoma smell 16.4 21.1 .27
Stoma bleeding 11.5 14.1 .47
Stoma leakage 10.6 12.0 .70
Painful stoma 7.0 6.3 .65
Noisy stoma 26.6 25 .65
Blood loss from
stump
8.0 7.1 .60
Mucus loss
from stump
14.6 17.9 .40
Impact of bowel
dysfunction on
Work or
household
activities
22.5 15.5 .03
Activities
outside the
house like
shopping
24.8 22.2 .41
Social activities
like theater or
cinema visiting
23.8 24.8 .89
Urinary function
Urinary
frequency
during the day
6.3 6.3 .77
Frequency
urinary
incontinence
57.1 54.2 .86
Use of pads for
urinary
incontinence
41.2 29.3 .18
Urine retention
after miction
24.2 18.0 .08
Need to urinate
again within 2
hours
26.2 25.9 .85
Stream
hesitation
23.1 18.9 .24
Difﬁculty
postponing
miction
28.2 24.7 .35
Weak urinary
stream
31.2 26.2 .16
Difﬁcult to start
miction
15.8 10.3 .06
Table 2 Continued
Mean Scores
CRT
Mean Scores
SC-PRT P
Satisfaction
Bowel functiona 83.1 76.3 .11
Urinary
functiona
71.2 81.2 <.01
A higher score for functioning (a) reﬂects better functioning, whereas a higher score for
symptoms represents a higher level of symptoms and decreased health-related quality of life.
Abbreviations: CRT ¼ Preoperative long-course (chemo) radiotherapy; SC-PRT ¼ preoperative
short-course radiotherapy.
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Patients who received CRT and SC-PRT reported no differences
in global health status and patient functioning (Table 3; Figure 1).
Although patients who received CRT reported signiﬁcantly more
nausea and vomiting compared with those who received SC-PRT
(mean score for CRT 5.9 vs. 1.3 for SC-PRT; P < .01), this dif-
ference is below a clinically relevant level. Moreover, patients who
received SC-PRT reported a trend towards more diarrhea than those
who received CRT (Table 3).
Discussion
This analysis of HRQL in patients who received CRT after a me-
dian follow-up time of 58 months shows no clinically relevant dif-
ferences in long-term HRQL and patient-reported symptoms
between CRT and SC-PRT, apart from less satisfaction with urinary
function reported by patients who received CRT. These results are in
line with the short-term HRQL of the Polish trial at 12 months after
treatment.7 Also, in a study comparing 10  2.9 Gy followed by
immediate surgery (n ¼ 108) versus 28  1.8 Gy with concomitant
chemotherapy and delayed surgery (n ¼ 117), no differences in
HRQL were found after 67 months, except for a better score for
physical functioning in the group that received CRT (mean scores 77
vs. 82, respectively;P¼ .04).20 These results support our ﬁndings that
long-term patient-reported HRQL is similar in patients who received
SC-PRT andCRT. In addition, a randomized trial comparing 25 2
Gy with or without 5-ﬂuorouracil and leucovorin, which included 78
patients with locally advanced rectal cancer, revealed no differences in
HRQL, evaluated with the EORTC QLQ-C30 several years after
treatment.21 Thus, chemotherapy does not seem to aggravate long-
term HRQL either when added to these radiotherapy schedules.
However, a study by Tiv et al, which included 1011 patients ran-
domized between PRT, CRT, PRT and postoperative chemotherapy,
and CRT and postoperative chemotherapy, found a decrease in some
long-term HRQL variables and an increase in diarrhea after adding
chemotherapy.22 In this study, 73% of the patients underwent
sphincter-sparing surgery, which can lead to the Low Anterior
Resection Syndrome. This syndrome is associated with a decrease of
HRQL.23
In addition to the long-term HRQL, analysis of the physician-
reported toxicity at 4 years in the Polish trial also demonstrated
no signiﬁcant difference in the crude overall incidence of late
toxicity (28.3% and 27.0%, respectively; P ¼ .81).24 Taken
together, these results show that long-term patient-reported HRQL
and physician-observed toxicity do not differ between SC-PRT and
Table 3 Scores of EORTC QLQ-C30
Mean Scores
CRT
Mean Scores
SC-PRT Pa
Global health status 79.6 78.9 .90
Functional scales
Physical functioning 84.5 82.6 .56
Role functioning 82.5 83.3 .73
Emotional functioning 86.9 86.3 .85
Cognitive functioning 84.0 84.1 .90
Social functioning 84.6 87.7 .27
Symptom items
Fatigue 23.8 22.5 .59
Nausea and vomiting 5.9 1.3 <.01
Pain symptoms 11.2 11.1 .92
Dyspnoea 11.8 11.6 .89
Insomnia 15.4 18.5 .42
Appetite loss 8.5 4.6 .12
Constipation 8.6 10.8 .51
Diarrhea 5.8 10.6 .09
Financial difﬁculties 9.5 6.8 .27
A higher score for functioning reﬂects better functioning, whereas a higher score for symptoms
represents a higher level of symptoms and decreased health-related quality of life.
Abbreviations: CRT ¼ Preoperative long-course (chemo) radiotherapy; EORTC ¼ European
Organisation for Research and Treatment of Cancer; SC-PRT ¼ preoperative short-course
radiotherapy.
aDifference between CRT and SC-PRT.
Lisette M. Wiltink et alCRT. This is in contrast with the thought that the higher dose per
fraction and short overall treatment time of SC-PRT would increase
the risk for late radiation-related toxicity compared with the lower
doses per fraction within CRT.
Acute toxicity after CRT and SC-PRT is reported in several
studies. The Polish trial found more early radiation toxicity after
CRT compared with SC-PRT (18.2% vs. 3.2%, respectively;
P < .001).24 This was also found in the randomized trial
comparing 25  2 Gy with or without 5-ﬂuorouracil and leu-
covorin: grade 3 and grade 4 acute toxicity was seen in 29% of
the patients after CRT and in 6% of the patients after RT
alone.25 However, as described above, none of these studies re-
ported a difference in the long-term toxicity or HRQL between
the treatment groups. Furthermore, in the Stockholm III trial, in
which patients were randomly allocated to either SC-PRT fol-
lowed by surgery within 1 week, SC-PRT and surgery after 4 to 8
weeks, or long-course radiotherapy (25  2 Gy) followed by
surgery after 4 to 8 weeks, no differences in the incidence of
severe acute radiation toxicity were found.26 Long-term toxicity
and HRQL of this trial should still be awaited.
For locally advanced tumors, down-staging is required to facili-
tate surgical resection with negative resection margins. The previ-
ously described Polish trial found more down-staging after CRT
(16%) compared with SC-PRT (1%).25 This difference in down-
staging did not result in a difference in local recurrence rate,
disease-free survival, or overall survival between the treatment
groups.24 Moreover, the Trans-Tasman Radiation Oncology Group
study, in which 326 rectal cancer patients were randomized between
5  5 Gy followed by early surgery and 6 courses of adjuvantchemotherapy versus 28  1.8 Gy and continuous ﬂuorouracil
followed by surgery in 4 to 6 weeks and 4 courses of adjuvant
chemotherapy, more down-staging was also found after CRT (45%)
compared with SC-PRT (28%). However, no signiﬁcant difference
in local recurrence rate, relapse-free survival, and overall survival
were found as well.27 Thus, while these trials reported more
downsizing and down-staging effects after CRT, this did not result
in differences in overall survival.
An alternative strategy is SC-PRT with delayed surgery to allow for
tumor regression. The interim results of the Stockholm III trial
showed pathologic complete responses of 0.8% after SC-PRT fol-
lowed by surgery within 1 week, 12.5% after SC-PRT and surgery
after 4 to 8 weeks, and 5% after long-course radiotherapy followed by
surgery after 4 to 8 weeks, indicating that there is more tumor
regression with SC-PRT and delayed surgery.26 At present, new
initiatives like the RAPIDO (Radiotherapy And Preoperative In-
duction therapy followed by Dedicated Operation) trial, which
compares CRT with SC-PRT followed by chemotherapy and
delayed surgery, are accruing patients.28 Long-term oncological
outcomes have to be awaited before an evidence-based decision
about the optimal patient selection and treatment can be made,
since no beneﬁt of CRT over SC-PRT is found based on local
control, survival, acute toxicity, and long-term HRQL, according
to the studies described above.
A strength of our study is the high response rate of 81.0% and a
median follow-up of 58 months. Also, while some studies excluded
patients with a stoma, we included these and even asked speciﬁc
stoma-related questions. These questions were very useful in our
analysis, since 78.8% of the CRT responders had a stoma at time of
the HRQL questionnaire. Study patients were treated with CRT,
since the Dutch guideline indicated this treatment by this tumor
inﬁltration depth and the lymph node involvement. The patients
included in the TME trial had less locally advanced tumors, and were
treated with SC-PRT. To be able to correct for this possible con-
founding by indication, we assessed the inﬂuence of the T status, N
status, the positive or negative circumferential resection margin, tu-
mor height, type of operation, and the presence of a stoma on HRQL
and urinary symptoms in the TME trial. None of these items inﬂu-
encedHRQL.However, gender and age were associated withHRQL,
so we corrected for these variables. The ﬁnding that the clinical T and
N status and tumor location have no or limited inﬂuence onHRQL is
also supported by an analysis of Guckenberger et al, who also stated
that no study in the literature has reported a correlation between
HRQL and any clinical T or N stage.20
In conclusion, patients who received CRT and SC-PRT reported
no clinically relevant differences in long-term HRQL and late
symptoms after a median follow-up period of 58 months, apart
from less satisfaction with urinary function reported by those who
received CRT. These results indicate that both approaches have a
comparable impact on long-term HRQL, and a preference for either
of them can therefore not be based on long-term HRQL.
Clinical Practice Points
 Both preoperative short-course radiotherapy (PRT) and preop-
erative long-course chemo radiotherapy (CRT) have shown to
reduce local recurrence rates. However, none of these neo-
adjuvant therapies resulted in an improved overall survival.Clinical Colorectal Cancer September 2016 - e97
Figure 1 Global Health Status and Patient Functioning Scores of the QLQ-C30
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Abbreviations: CRT ¼ preoperative long-Course (chemo) radiotherapy; HRQL ¼ health-related quality of life; SC-PRT ¼ preoperative short-Course radiotherapy. A higher Score for functioning
represents better functioning.
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e98 - After a short follow-up time, no differences in health-related quality
of life (HRQL) are reported between both treatment schedules.
 After a median follow-up of 58 months, the only clinically
relevant difference in HRQL between the groups was less satis-
faction with urinary function indicated by patients who received
CRT (mean score for CRT 71.2 vs. 81.2 for SC-PRT; P < .01).
 No beneﬁt of CRT over SC-PRT is found based on long-term
HRQL, acute toxicity, local control, and survival.
 However, after CRT, more downsizing and down-staging of rectal
cancer tumors is reported. On the other hand, tumor regression is
also found after SC-PRT followed by delayed surgery.
 Long-term oncological outcomes of new initiatives like the RAP-
IDO trial have to be awaited before an evidence-based decision
about the optimal patient selection and treatment can be made.Acknowledgments
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Items of the Questionnaire on Bowel and Urinary Function
Bowel function
Mean bowel frequency at day and night
Description stool
Anal blood and mucus loss
Fecal incontinence at day and night
Use of pads for fecal incontinence
Ability to delay bowel emptying
Stoma function
Peristomal skin irritation
Stoma smell
Stoma bleeding
Stoma leakage
Painful stoma
Noisy stoma
Blood and mucus loss from stump
Impact of bowel dysfunction on
Work or household activities
Activities outside the house like shopping
Social activities like theater or cinema visiting
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Urinary frequency during the day
Frequency urinary incontinence
Relation of urinary incontinence to stress and urge
Use of pads for urinary incontinence
Urine-retention after miction
Need to urinate again within 2 hours
Stream hesitation
Difﬁculty postponing miction
Weak urinary stream
Difﬁcult to start miction
Satisfaction with bowel and urinary function
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